

IMMUNOTHERAPY OF B-CELL MALIGNANCIES USING ANTI-CD22 ANTIBODIES

Publication number: JP2002544173 (T)

Publication date: 2002-12-24

Inventor(s):

Applicant(s):

Classification:

- international: A61K38/00; A61K31/166; A61K31/17; A61K31/192; A61K31/475; A61K31/519; A61K31/573; A61K31/675; A61K31/7048; A61K38/21; A61K39/395; A61K51/00; A61P35/00; A61P35/02; C07K16/28; A61K38/00; A61K31/166; A61K31/17; A61K31/185; A61K31/475; A61K31/519; A61K31/57; A61K31/675; A61K31/7042; A61K38/21; A61K39/395; A61K51/00; A61P35/00; C07K16/18; (IPC1-7): A61K39/395; A61K31/166; A61K31/17; A61K31/192; A61K31/475; A61K31/519; A61K31/573; A61K31/675; A61K31/7048; A61K38/00; A61K38/21; A61K51/00; A61P35/02

- European: A61K39/395; C07K16/28A

Application number: JP20000616820T 20000510

Priority number(s): US19990307816 19990510; WO2000US12583 20000510

Also published as:

- WO0067795 (A1)
- EP1178826 (A1)
- CA2373618 (A1)
- AU774044 (B2)
- AU4829600 (A)

Abstract not available for JP 2002544173 (T)

Abstract of corresponding document: **WO 0067795 (A1)**

B-cell malignancies, such as the B-cell subtype of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, are significant contributors to cancer mortality. The response of B-cell malignancies to various forms of treatment is mixed. Traditional methods of treating B-cell malignancies, including chemotherapy and radiotherapy, have limited utility due to toxic side effects. Immunotherapy with anti-CD20 antibodies have also provided limited success. The use of antibodies that bind with the CD22 or CD19 antigen, however, provides an effective means to treat B-cell malignancies such as indolent and aggressive forms of B-cell lymphomas, and acute and chronic forms of lymphatic leukemias. Moreover, immunotherapy with anti-CD22 and/or anti-CD19 antibodies requires comparatively low doses of antibody protein, and can be used effectively in multimodal therapies.

Data supplied from the **esp@cenet** database — Worldwide